By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Inhibrx Biosciences Inc.

Inhibrx Biosciences Inc. (INBX)

NASDAQ Currency in USD
$175.00
-$2.88
-1.62%
Last Update: 18 Jul 2026, 14:27
$2.71bn
Market Cap
-20.86
P/E Ratio (TTM)
Forward Dividend Yield
$124.10-$224.89
52 Week Range

INBX Stock Price Chart

Explore Inhibrx Biosciences Inc. interactive price chart. Choose custom timeframes to analyze INBX price movements and trends.

INBX Company Profile

Discover essential business fundamentals and corporate details for Inhibrx Biosciences Inc. (INBX) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

29 May 2024

Employees

109.00

CEO

Mark Lappe

Description

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

INBX Financial Timeline

Browse a chronological timeline of Inhibrx Biosciences Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 12 Aug 2026

EPS estimate is -$2.28.

Earnings released on 14 May 2026

EPS came in at -$2.15 surpassing the estimated -$2.37 by +9.28%.

Earnings released on 19 Mar 2026

EPS came in at -$2.11 falling short of the estimated -$2.08 by -1.44%.

Earnings released on 14 Nov 2025

EPS came in at -$2.28 falling short of the estimated -$2.08 by -9.62%.

Earnings released on 13 Aug 2025

EPS came in at -$1.85 surpassing the estimated -$2.92 by +36.64%, while revenue for the quarter reached $1.30m .

Earnings released on 14 May 2025

EPS came in at -$2.80 falling short of the estimated -$2.55 by -9.80%.

Earnings released on 17 Mar 2025

EPS came in at -$3.09 falling short of the estimated -$2.88 by -7.29%, while revenue for the quarter reached $100.00k .

Earnings released on 14 Nov 2024

EPS came in at -$2.84 surpassing the estimated -$3.06 by +7.19%.

Earnings released on 13 Aug 2024

EPS came in at $125.48 surpassing the estimated -$3.60 by +3.59k%, while revenue for the quarter reached $100.00k .

Earnings released on 3 Jun 2024

EPS came in at -$1.44 falling short of the estimated -$1.04 by -38.46%.

Dividend declared on 30 May 2024

A dividend of $0.85 per share was announced, adjusted to $0.85. The dividend was paid on 20 Jun 2024.

Earnings released on 28 Feb 2024

EPS came in at -$1.73 falling short of the estimated -$1.07 by -61.68%, while revenue for the quarter reached $1.63m , beating expectations by +3.17k%.

Earnings released on 9 Nov 2023

EPS came in at -$1.10 falling short of the estimated -$1.01 by -8.91%, while revenue for the quarter reached $119.00k , beating expectations by +138.00%.

Earnings released on 7 Aug 2023

EPS came in at -$1.08 falling short of the estimated -$1.02 by -5.88%, while revenue for the quarter reached $30.00k .

Earnings released on 8 May 2023

EPS came in at -$1.12 falling short of the estimated -$0.84 by -33.33%, while revenue for the quarter reached $17.00k , missing expectations by -88.67%.

Earnings released on 6 Mar 2023

EPS came in at -$0.95 falling short of the estimated -$0.80 by -18.75%, while revenue for the quarter reached $274.00k , missing expectations by -72.43%.

Earnings released on 7 Nov 2022

EPS came in at -$0.90 surpassing the estimated -$1.01 by +10.89%, while revenue for the quarter reached $278.00k , missing expectations by -56.11%.

Earnings released on 8 Aug 2022

EPS came in at -$0.97 falling short of the estimated -$0.84 by -15.48%, while revenue for the quarter reached $711.00k , missing expectations by -33.50%.

Earnings released on 9 May 2022

EPS came in at -$0.80 falling short of the estimated -$0.62 by -29.03%, while revenue for the quarter reached $915.00k , missing expectations by -17.01%.

Earnings released on 28 Feb 2022

EPS came in at -$0.55 falling short of the estimated -$0.53 by -3.77%, while revenue for the quarter reached $2.84m , beating expectations by +134.70%.

Earnings released on 9 Nov 2021

EPS came in at -$0.54 surpassing the estimated -$0.57 by +5.26%, while revenue for the quarter reached $2.51m , beating expectations by +67.20%.

Earnings released on 9 Aug 2021

EPS came in at -$0.55 falling short of the estimated -$0.51 by -7.84%, while revenue for the quarter reached $918.00k , beating expectations by +11.95%.

INBX Stock Performance

Access detailed INBX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run